In Tanzania, behcet Disease is managed by rheumatologists. Behcet disease (Behcet syndrome) is a chronic systemic vasculitis affecting blood vessels of all sizes and types, characterized by recurrent oral ulcers, genital ulcers, ocular inflammation, and skin lesions, sometimes with arthritis, vascular, gastrointestinal, or central nervous system involvement. Prevalence is highest along the historic Silk Road, with rates of 80-420 per 100,000 in Turkey and 50-150 per 100,000 in Iran, Iraq, Japan, and Korea, falling to 0.3-7 per 100,000 in northern Europe and the United States.
Behcet disease (ICD-10: M35.2) is a systemic variable-vessel vasculitis of unknown cause, classified among autoinflammatory and autoimmune disorders, in which dysregulated innate and adaptive immunity produces neutrophil-rich inflammation in mucocutaneous, ocular, articular, vascular, gastrointestinal, and neurological tissues. The genetic background is strongly associated with HLA-B*51 (carriage in 50-70% of patients in endemic countries versus 10-20% of controls); other susceptibility loci include ERAP1, IL10, and IL23R-IL12RB2. Environmental triggers (streptococcal antigens, herpes simplex virus, gut microbial dysbiosis) interact with this genetic background to produce hyperactive Th1, Th17, and gamma-delta T-cell responses, IL-17 and TNF-alpha elevation, and pathergic neutrophil hyperreactivity. The 2014 International Criteria for Behcet's Disease (ICBD) uses a points-based score combining recurrent oral ulcers, genital ulcers, ocular lesions (uveitis or retinal vasculitis), skin lesions (pseudofolliculitis, erythema nodosum), vascular involvement (deep vein thrombosis, large vessel aneurysm), neurological involvement, and a positive pathergy test.
The key symptoms of Behcet Disease are: Painful recurrent oral aphthous ulcers — typically more than 3 episodes per year — located on the buccal mucosa, tongue, lips, and palate; ulcers heal in 1-3 weeks usually without scarring., Painful genital ulcers — on the scrotum, vulva, or perianal area — that are typically larger than oral ulcers and may scar., Acute uveitis with eye pain, redness, photophobia, blurred vision, and floaters; can be anterior, posterior, or both, often bilateral., Papulopustular skin lesions resembling folliculitis or acne but in unusual distribution (back, buttocks, lower limbs); positive pathergy with a sterile pustule developing within 24-48 hours at a needle prick site., Erythema nodosum-like tender red nodules on the legs, healing with hyperpigmentation., Non-erosive oligoarticular arthritis affecting knees, ankles, wrists, and elbows; symmetrical or asymmetrical, often resolving spontaneously over weeks., Deep vein thrombosis of the legs or upper extremities, recurrent superficial thrombophlebitis, and venous insufficiency..
Diagnosis is clinical and based on internationally agreed criteria; no single laboratory or imaging test is pathognomonic. The 1990 International Study Group criteria require recurrent oral ulcers (at least 3 episodes per year) plus 2 of: recurrent genital ulcers, ocular lesions (uveitis or retinal vasculitis), defined skin lesions (pseudofolliculitis, erythema nodosum), or positive pathergy test. The 2014 International Criteria for Behcet's Disease (ICBD) introduces a points-based system with greater sensitivity (94%) and similar specificity. A pathergy test — sterile pustule formation within 24-48 hours at a needle prick site — is highly specific in endemic populations but has variable sensitivity. HLA-B*51 genotyping supports the diagnosis in equivocal cases but is neither necessary nor sufficient. Comprehensive evaluation at diagnosis includes complete blood count, ESR, CRP, urinalysis, comprehensive metabolic panel, slit-lamp and dilated fundus examination by ophthalmology, and screening for vascular and neurological involvement based on symptoms. CT or MR angiography is indicated for suspected vascular involvement; MRI brain for suspected neuro-Behcet; ileocolonoscopy for gastrointestinal symptoms. Differential diagnosis includes complex aphthosis without systemic features, herpes simplex, Crohn's disease, MAGIC syndrome (mouth and genital ulcers with inflamed cartilage), lupus, reactive arthritis, and inflammatory bowel disease. Activity is assessed periodically with the Behcet Disease Current Activity Form (BDCAF) and organ-specific damage indices. Patients are stratified by phenotype to guide treatment intensity.
Long-term outcomes vary by phenotype, age at onset, and access to modern immunosuppression. Mucocutaneous Behcet has an excellent prognosis with normal life expectancy and minimal long-term damage when treated. Ocular Behcet without biologic therapy led to blindness in 25% within 5 years in historic cohorts; modern treatment has reduced this to under 5% in specialist clinics. Vascular and neurological involvement carry the highest mortality: untreated pulmonary artery aneurysms have a 5-year mortality of 25-50%; cyclophosphamide and TNF-alpha inhibitors have improved this substantially. Disease activity typically peaks in the first 7 years and declines thereafter, although organ damage accrues over decades. Standardized mortality ratio in Behcet is 1.4-1.7 in Turkish cohorts, with vascular and neurological complications being the dominant causes of premature death. Young men with onset under 25 have the worst prognosis. Pregnancy outcomes are generally favorable with disease control; medication adjustments (avoiding teratogens) are essential.
Behcet disease is rare in non-endemic countries and frequently misdiagnosed. Rheumatology assessment confirms the diagnosis, stages organ involvement, and initiates organ-specific therapy. Ophthalmology, vascular surgery, neurology, and gastroenterology involvement is essential when their respective organs are affected; multidisciplinary specialist clinics produce the best outcomes.
Find specialists →Mucocutaneous flares: ulcers heal in 1-3 weeks. Acute uveitis episodes: 4-12 weeks to resolution with treatment. Vascular events: 3-12 months of intensive immunosuppression with prolonged maintenance. Neurological parenchymal disease: months to years; permanent damage is common but not universal. Maintenance therapy is lifelong in most patients.
Regular moderate aerobic activity (walking, swimming, cycling) is recommended during remission. Avoid contact sports during anticoagulation. Patients with ocular inflammation should avoid activities risking eye trauma. Cardiac rehabilitation is recommended after vascular interventions.
Choose a rheumatologist with documented experience in vasculitis or Behcet disease, ideally working in a tertiary center with on-site ophthalmology, vascular surgery, and neurology. Multidisciplinary Behcet clinics improve diagnostic accuracy and treatment escalation, with measurable reductions in blindness and major organ damage.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Tanzania.
Apply as specialist →Specialists who treat Behcet Disease. Get expert guidance and personalized care.